Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.
COVID-19
CRSwNP
SARS-CoV-2
biologics
chronic rhinosinusitis
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
28
05
2020
revised:
02
10
2020
accepted:
04
10
2020
pubmed:
20
10
2020
medline:
19
3
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes. The current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet. Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic. Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.
Sections du résumé
BACKGROUND
Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes.
METHODS
The current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet.
RESULTS
Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic.
CONCLUSION
Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.
Substances chimiques
Adrenal Cortex Hormones
0
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
677-688Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology. 2020,58(3):299-301.
Iacobucci G. Sixty seconds on … anosmia. BMJ. 2020;368:m1202.
Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Organization WH.Coronavirus disease (COVID-19 pandemic). 2020 01.04.2020].
Luers JC, Klussmann JP, Guntinas-Lichius O. The Covid-19 pandemic and otolaryngology: What it comes down to? Laryngorhinootologie. 2020,99(5):287-291.
Control, E.C.f.D.P.a. Situation update worldwide. 2020 07.04.2020020].
Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.
Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020,75(7):1730-1741.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203.
Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe-an underestimated disease. A GA2LEN study. Allergy. 2011;66(9):1216-1223.
Hirsch AG, Stewart WF, Sundaresan AS, et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy. 2017;72(2):274-281.
Ostovar A, Fokkens WJ, Vahdat K, Raeisi A, Mallahzadeh A, Farrokhi S. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology. 2018;57(1):43-48.
Shi JB, Fu QL, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015;70(5):533-539.
Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. 2020,130(7):1787.
Dietz de Loos D, Lourijsen ES, Wildeman MAM, et al. Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. J Allergy Clin Immunol. 2019;143(3):1207-1214.
Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012. 23: p. 3 p preceding table of contents, 1-298.
Rosenfeld RM. Clinical practice guideline adult sinusitis. Otolaryngology - head and neck surgery. Orlando, FL: Elsevier; 2007:S45 S.
Fokkens WJ. EPOS2020: a major step forward. Rhinology. 2020;58(1):1.
Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
Soyka MB, Wawrzyniak P, Eiwegger T, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4. J Allergy Clin Immunol. 2012;130(5):1087.
Klimek L, Koennecke M, Hagemann J, Wollenberg B, Becker S. Immunologie der polyposis nasi als grundlage für eine therapie mit biologicals. Hno. 2018;67(1):15-26.
Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449.
Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenberg B. Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo J Int. 2018;27(2):56-65.
Tsetsos N, Goudakos JK, Daskalakis D, Konstantinidis I, Markou K. Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2018;56(1):11-21.
Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297-1305.
Fokkens WJ. Evidence-based and precision medicine two of a kind. Rhinology. 2017;55(1):1-2.
Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 2013;68(1):1-7.
Hox V00, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1.
Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.
Liao B, Liu J-x, Li Z-y, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy. 2018;73(7):1459-1469.
Philpott CM, Erskine S, Hopkins C, et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK national chronic rhinosinusitis epidemiology study. Respir Res. 2018;19(1):129.
Wu D, Bleier BS, Li L, et al. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(4):1297.
Khan A, Vandeplas G, Huynh T, et al. The global allergy and asthma european network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2018;57(1):32-42.
Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 2016;9:45-53.
Lin DC, Chandra RK, Tan BK, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25(4):205-208.
Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Res J. 2015;46(5):1308-1321.
De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22.
Seys SF, Scheers H, Van den Brande P, et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res. 2017;18(1):39.
Zhang Y, Derycke L, Holtappels G, et al. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps. Allergy. 2018;74(1):131-140.
Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875-879.
GINA, Global Strategy for Asthma Management and Prevention (2020 update). 2020; https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed October 28, 2020.
Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22-S209.
Rondón C, Dávila I, Navarro Pulido AM, et al. Clinical management and use of health care resources in the treatment of nasal polyposis in spanish allergy centers: the POLAR study. J Investig Allergol Clin Immunol. 2015;25(4):276-282.
Stuck BA, Beule A, Jobst D, et al. Guideline for "rhinosinusitis"-long version : S2k guideline of the German college of general practitioners and family physicians and the german society for oto-rhino-laryngology, head and neck surgery. HNO. 2018;66(1):38-74.
Wei CC, Adappa ND, Cohen NA. Use of topical nasal therapies in the management of chronic rhinosinusitis. The Laryngoscope. 2013;123(10):2347-2359.
Chong LY, Head K, Hopkins C, et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011996.
Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA. 2015;314(9):926-939.
Klimek L, Bachert C. Current aspects of nasal glucocorticosteroid therapy. HNO. 2000;48(7):544-555.
Pundir V, Pundir J, Lancaster G, et al. Role of corticosteroids in functional endoscopic sinus surgery-a systematic review and meta-analysis. Rhinology. 2016;54(1):3-19.
Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2018;74(2):273-283.
Head K, Chong LY, Hopkins C, et al. Short-course oral steroids alone for chronic rhinosinusitis. The Cochrane database of systematic reviews, 2016;4:CD011991.
Head K, Chong LY, Hopkins C, et al. Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis. The Cochrane database of systematic reviews, 2016;4:CD011992.
Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204.
Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.
Recovery Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020.
Kirsche H, Klimek L. ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis : Differentialdiagnostik und Therapie. Hno 2015;63(5):357-63.
Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am. 2009;29(4):669-675.
Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. Allergy. 2018;74(1):28-39.
Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Exp Rev Clin Immunol. 2017;13(5):425-437.
Sanofi-Aventis_Deutschland_GmbH D. 300 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt, 2020:21.
Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312-2319.
Hopkins C, Surda P, Bast F, Hettige R, Walker A, Hellings Pw. Prevention of chronic rhinosinusitis. Rhinology. 2018;56(4):307-315.
Kilty SJ, Lasso A, Mfuna-Endam L, Desrosiers M. Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps. Rhinology 2018;56(2):155-157.
Rudmik L, Soler Z, Hopkins C, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology. 2016;54(2):117-128.
Bousquet J, Akdis C, Jutel M. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy. 2020;75(10):2440-2444.
Hayward G, Thompson M J, Perera R, et al. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2015;10:CD008116.
Keith PK, Dymek A, Pfaar O, et al. Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study. Prim Care Respir J. 2012;21(3):267-275.
Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116(6):1289-1295.
Puhakka T, Mäkelä MJ, Malmström K, et al. The common cold: effects of intranasal fluticasone propionate treatment. J Allergy Clin Immunol. 1998;101(6 Pt 1):726-731.
Klimek L, Förster-Ruhrmann U, Becker S, et al. Stellungnahme zur Anwendung von Glukokortikosteroiden bei entzündlichen Erkrankungen der oberen Atemwege. Laryngo- rhino- otologie. 2020:99(5):280-281.
Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations-a GA(2) LEN-DARE systematic review. Allergy. 2011;66(4):458-468.
Darveaux JI, Lemanske RF Jr. Infection-related asthma. J Allergy Clin Immunol Pract. 2014;2(6):658-663.
Hewitt R,Farne H, Ritchie A, Luke E, Johnston SL, Mallia P The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158-174.
DGP: Michael Pfeifer ML, Korn S, et al- Asthma-Patienten und COVID-19: Lungenexperten raten: Therapie mit inhalierbaren Steroiden (ICS) unverändert fortführen. 2020: https://pneumologie.de/fileadmin/user_upload/Aktuelles/2020-03-16_Statement_Asthma_und_COVID-19_F.pdf.
Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020;95:183-191.
Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy. 2013;68(7):829-835.
Abidi K, Khoudri I, Belayachi J, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Critical care (London, England) 2008;12(2):R59.
Kulaylat AS, Buonomo EL, Scully KW, et al. Development and validation of a prediction model for mortality and adverse outcomes among patients with peripheral eosinopenia on admission for clostridium difficile infection. JAMA surgery. 2018;153(12):1127-1133.
Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015-1027.
Ghazi A, Trikha A, Calhoun WJ. Benralizumab-a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12(1):113-118.
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. Allergy. 2020;75(5):1023-1042.
Howarth P, Chupp G, Nelsen LM et al. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol. 2020;145(6):1713-1715.
Dupilumab core company data sheet. 2019.
CHMP, E.M.A. Assessment report -. Dupixent. 2017 01.04.2020].
Klimek L, Pfaar O, Worm M. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie - ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI. Use of biologicals in allergic and type-2 inflammatory diseases in times of the current COVID-19 pandemic - Position paper of AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI. Allergologie. 2020;43(7):255.
Vultaggio A, Agache I, Akdis CA, et al. Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement. Allergy. 2020;75:2764-2774.
Van Gerven L, Hellings PW, Cox T, et al. Personal protection and delivery of rhinologic and endoscopic skull base procedures during the COVID-19 outbreak. Rhinology. 2020;58(3):289-294.
Workman AD, Welling DB, Carter BS, et al. Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. Int Forum Allergy Rhinol. 2020;10(7):798-805.
Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971.
Qin J, You C, Lin Q, Hu T, Yu S, Zhou XH. Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. Sci Adv. 2020;6(33):eabc1202.
CDC.gov. Center for Disease Control and Prevention. 2020 01.04.2020].
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-1179.
Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One. 2012;7(4):e35797.
Criado PR, Criado RFJ, Pincelli TP et al. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. Int J Dermatol. 2020;59(10):1294-1295.
Förster-Ruhrmann U, Szczepek AJ, Bachert C, Olze H. COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab. J Allergy Clin Immunol. 2020;146(1):218.
Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab. Allergy. 2020;75(10):2705-2708.